Related Experiment Video
Updated: Jan 9, 2026
Matrix-based DNA Extraction for Targeted Next-Generation Sequencing on Decontaminated Sputum Samples
Published on: June 6, 2025
A retrospective analysis of pulmonary and extra-pulmonary tuberculosis drug resistance in Punjab, Pakistan
Zomer Sardar1, Carla Y Kim2, Jackson A Roberts2
1Department of Neurology, Columbia University Irving Medical Center, New York, NY, United States; Department of Neurology, Mayo Hospital, Lahore, Punjab, Pakistan.
Background:
This study aims to investigate drug resistance patterns in pulmonary and extra-pulmonary tuberculosis (TB), including central nervous system (CNS)-TB, using the largest reference multidrug resistance laboratory in Punjab, Pakistan.
Methods:
Retrospective data from 2012 to 2022 were collected from 1410 patients referred to the multidrug resistant (MDR)-TB laboratory of Mayo Hospital, Lahore, Pakistan. The drug resistant (DR) testing was performed on sputum or pleural fluid in patients with pulmonary tuberculosis, and on cerebrospinal fluid in patients with CNS-TB.
Results:
The mean age was 35 ± 15.9 years, with a higher proportion of females (50.5 %; 712). Of the cases, 96.5 %; 1361 presented with pulmonary TB, while 4 % (56) had isolated extra-pulmonary TB. Among the extra-pulmonary cases, 1.3 % (18) had CNS-TB. A significant percentage (67.8 %; 956) exhibited MDR-TB, with 25.3 % (356) showing rifampicin resistance. Moreover, 6 % (85) demonstrated resistance to both first and second-line drugs, with 0.4 % (5) resistant to all first-line anti-TB drugs. Of the CNS-TB cases, 56 % (10) had confirmed rifampicin resistance. Most patients (81.9 %; 1152) had previously received first-line anti-TB drugs.
Conclusion:
This study underscores the high burden of DR-TB in endemic regions, and the need for further large-scale investigations to better understand resistance patterns and inform effective management strategies.
More Related Videos
10:04Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
Published on: September 5, 2017
10:29A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
Published on: March 24, 2017
Related Concept Videos
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
01:31Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
01:28Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
01:26Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
01:29Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...